Pfizer Inc. [NYSE: PFE] closed the trading session at $39.73 on 07/02/21. The day’s price range saw the stock hit a low of $39.38, while the highest price level was $39.83. The company report on July 5, 2021 that Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories.
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products for patients in Greater China and other parts of Asia, announced that Spero Therapeutics, Inc. (Nasdaq: SPRO), a licensing partner of Everest Medicines, entered into a regional licensing agreement with Pfizer Inc. (NYSE: PFE) for SPR206, Spero’s intravenously (IV)-administered next-generation polymyxin product candidate being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting.
Under the terms of the licensing agreement, Spero has granted Pfizer the rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories. In exchange for these rights, Spero is eligible to receive up to $80 million in development and sales milestones, and high single digit to low double-digit royalties on net sales of SPR206 in these territories. Pfizer has also made a $40 million equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs.
The stocks have a year to date performance of 7.93 percent and weekly performance of 1.92 percent. The stock has been moved at 7.93 percent over the last six months. The stock has performed 1.95 percent around the most recent 30 days and changed 9.51 percent over the most recent 3-months.
If compared to the average trading volume of 26.17M shares, PFE reached to a volume of 16595888 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $42.97 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Sector Perform. The new note on the price target was released on April 07, 2021, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $41, while DZ Bank analysts kept a Buy rating on PFE stock. On December 16, 2020, analysts decreased their price target for PFE shares from 43 to 42.
The Average True Range (ATR) for Pfizer Inc. is set at 0.53, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.77. The Price to Book ratio for the last quarter was 3.23, with the Price to Cash per share for the same quarter was set at 2.45. Price to Free Cash Flow for PFE in the course of the last twelve months was 44.65 with Quick ratio for the last quarter at 1.20.
PFE stock trade performance evaluation
Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.92. With this latest performance, PFE shares gained by 1.95% in over the last four-week period, additionally plugging by 7.93% over the last 6 months – not to mention a rise of 21.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 55.76, with the RSI for the last a single of trading hit 59.03, and the three-weeks RSI is set at 55.10 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 39.37, while it was recorded at 39.33 for the last single week of trading, and 37.34 for the last 200 days.
Pfizer Inc. [PFE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +21.52 and a Gross Margin at +71.21. Pfizer Inc.’s Net Margin is presently recorded at +16.67.
Return on Total Capital for PFE is now 8.14, given the latest momentum, and Return on Invested Capital for the company is 6.93. Return on Equity for this stock inclined to 11.05, with Return on Assets sitting at 4.34. When it comes to the capital structure of this company, Pfizer Inc. [PFE] has a Total Debt to Total Equity ratio set at 65.26. Additionally, PFE Total Debt to Total Capital is recorded at 39.49, with Total Debt to Total Assets ending up at 26.76. Long-Term Debt to Equity for the company is recorded at 60.48, with the Long-Term Debt to Total Capital now at 36.60.
Reflecting on the efficiency of the workforce at the company, Pfizer Inc. [PFE] managed to generate an average of $88,981 per employee. Receivables Turnover for the company is 5.03 with a Total Asset Turnover recorded at a value of 0.26.Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for Pfizer Inc. [PFE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 12.57%.
Pfizer Inc. [PFE]: Insider Ownership positions
There are presently around $145,656 million, or 66.60% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 450,914,119, which is approximately 0.66% of the company’s market cap and around 0.04% of the total institutional ownership; BLACKROCK INC., holding 405,733,970 shares of the stock with an approximate value of $16.12 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.92 billion in PFE stock with ownership of nearly -1.679% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,376 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 143,333,589 shares. Additionally, 1,219 investors decreased positions by around 173,586,848 shares, while 203 investors held positions by with 3,349,218,263 shares. The mentioned changes placed institutional holdings at 3,666,138,700 shares, according to the latest SEC report filing. PFE stock had 156 new institutional investments in for a total of 18,057,494 shares, while 132 institutional investors sold positions of 13,515,952 shares during the same period.